Tumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors. Satumomab Pendetide (trade name: OncoScint®) is no longer commercially available.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estrone | Estrone may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estradiol | Estradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Mestranol | Mestranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estriol | Estriol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Tibolone | Tibolone may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Zeranol | Zeranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Equol | Equol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Promestriene | Promestriene may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Formononetin | Formononetin may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Estetrol | Estetrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Indium In-111 satumomab pendetide. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indium In-111 satumomab pendetide. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Indium In-111 satumomab pendetide. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Indium In-111 satumomab pendetide. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Indium In-111 satumomab pendetide. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indium In-111 satumomab pendetide. |
| Infliximab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Infliximab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rituximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Basiliximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Muromonab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibritumomab tiuxetan. |
| Tositumomab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alemtuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Capromab pendetide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Natalizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Palivizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daclizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Technetium Tc-99m arcitumomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eculizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Panitumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ranibizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Galiximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pexelizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Afelimomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Epratuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bectumomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Oregovomab. |
| IGN311 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IGN311. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Adecatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Canakinumab. |